## Tardive Dyskinesia: Recognition and Management ### Clinical Presentation and Diagnosis **Key Point:** Tardive dyskinesia (TD) is an involuntary movement disorder that develops after prolonged antipsychotic exposure (typically >3 months at therapeutic doses). It is characterized by repetitive, purposeless movements of the orofacial region, limbs, and trunk. ### Features of Tardive Dyskinesia in This Case | Feature | Present in Patient | Significance | |---------|-------------------|---------------| | Orofacial dyskinesia (lip smacking, tongue protrusion) | Yes | Classic TD presentation | | Duration >3 months on antipsychotic | Yes (6 months olanzapine) | Meets temporal criterion | | Involuntary nature | Yes | Distinguishes from akathisia | | Worsens with emotional stress | Yes | Typical TD behavior | | No recent medication change | Yes | Rules out acute dystonia | **High-Yield:** Olanzapine, despite being a second-generation antipsychotic, carries a moderate-to-high risk of tardive dyskinesia, particularly at higher doses (>10 mg/day) and with longer duration of use. ### Why Benztropine is NOT Appropriate **Warning:** Anticholinergic agents (benztropine, trihexyphenidyl) can **worsen** tardive dyskinesia by unmasking or exacerbating involuntary movements. They are used for acute dystonia and akathisia, NOT for TD. ### Management Algorithm for Tardive Dyskinesia ```mermaid flowchart TD A[Tardive Dyskinesia Diagnosed]:::outcome --> B{Psychiatric stability?}:::decision B -->|Stable| C[Switch to low-TD-risk antipsychotic]:::action B -->|Unstable| D[Continue current agent + add vestigial suppressor]:::action C --> E[Options: Aripiprazole, Quetiapine, Clozapine]:::outcome D --> F[Consider: Valbenazine, Deutetrabenazine]:::action E --> G[Monitor for TD improvement over weeks-months]:::action F --> G G --> H{TD resolved?}:::decision H -->|Yes| I[Continue new regimen]:::outcome H -->|No| J[Add vestigial suppressor or optimize dose]:::action ``` ### Antipsychotic Risk Stratification for Tardive Dyskinesia | Risk Category | Agents | Mechanism | |---------------|--------|----------| | **Very Low** | Aripiprazole, quetiapine, clozapine | Partial D2 agonism or low D2 affinity | | **Low** | Risperidone (low dose), paliperidone (low dose) | Moderate D2 blockade | | **Moderate-High** | Olanzapine (>10 mg), haloperidol | High D2 blockade + long duration | | **High** | Typical antipsychotics (high-dose) | Sustained D2 blockade | **Clinical Pearl:** Aripiprazole is particularly useful in patients with established TD because its partial D2 agonist activity may actually improve TD while maintaining antipsychotic efficacy. ### Pharmacological Suppressors of Tardive Dyskinesia 1. **Valbenazine** (VMAT2 inhibitor) — FDA-approved for TD; dose 40–80 mg/day 2. **Deutetrabenazine** (VMAT2 inhibitor) — FDA-approved for TD; dose 12–48 mg/day 3. **Tetrabenazine** (older VMAT2 inhibitor) — off-label; risk of depression **High-Yield:** Valbenazine and deutetrabenazine deplete monoamines (dopamine, serotonin, norepinephrine) in synaptic vesicles, reducing involuntary movement transmission. ### Why Vitamin E is NOT Recommended **Warning:** High-dose vitamin E supplementation has NOT been shown to be effective for tardive dyskinesia in rigorous trials. It is no longer recommended as monotherapy or adjunctive treatment. ### Monitoring and Follow-up - Reassess TD severity using **Abnormal Involuntary Movement Scale (AIMS)** at baseline and 4–8 weeks post-intervention - Monitor psychiatric symptoms closely during antipsychotic switch - Educate patient on TD risk and informed consent for continued antipsychotic use - Consider dose reduction of original antipsychotic if switching is not immediately feasible [cite:Stahl's Essential Psychopharmacology 6e Ch 5; American Psychiatric Association Practice Guideline for Antipsychotic Use]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.